Press Release
Florham Park, NJ, August 2nd, 2023
Xiromed LLC today announced the launch of Betamethasone Valerate Foam, 0.12%, generic to Luxiq®. Annual market sales for Luxiq® and its generics for the twelve-month period ending June, 2023 were $4.4 million, according to IQVIA™. Betamethasone Valerate Foam, 0.12% is a medium potency topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp.
“Xiromed’s portfolio continues to grow as we expand our offering of topical generic pharmaceutical products to the US market with the launch of Betamethasone Valerate Foam, manufactured at our Guadalajara, Spain facility, Laboratorios Liconsa,” commented Rob Spina, CEO of Xiromed.
Xiromed LLC, located in Florham Park, NJ, is the US generic division of Insud Pharma, S.L., a global pharmaceutical group headquartered in Madrid, Spain. Xiromed is focused on developing and commercializing high quality generic pharmaceutical products for the US market. In addition to its commercial portfolio of generics available in the US, Xiromed has a robust development portfolio of generic pharmaceutical products in various stages of development, including injectable, inhalation and complex generic products. Learn more at http://www.xiromed.com/usa/
